Dolutegravir submitted to EU, US and Canadian regulatory agencies

On 17 December 2012, ViiV Healthcare issued a press release announcing the submission of regulatory applications in the European Union (EU), United States (US) and Canada for the investigational integrase inhibitor dolutegravir (S/GSK1349572).

These submissions are for the treatment of HIV infection in adults and adolescents (children aged 12 years and older).


ViiV press release. ViiV Healthcare announces regulatory submissions for dolutegravir in the EU, US and Canada. 17 December 2012.

Links to other websites are current at date of posting but not maintained.